association (references)

References for: association

Full identifier: http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#association

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#type type	http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/2000/01/rdf-schema#label label	adasuve psychomotor agitation is defined in dsm iv as excessive motor activity associated with a feeling of inner tension patients experiencing agitation often manifest behaviors that interfere with their care e g threatening behaviors escalating or urgently distressing behavior self exhausting behavior leading clinicians to the use of rapidly absorbed antipsychotic medications to achieve immediate control of the agitation see clinical studies 14 the efficacy of adasuve was established in one study of acute agitation in patients with schizophrenia and one study of acute agitation in patients with bipolar i disorder see clinical studies 14 limitations of use as part of the adasuve rems program to mitigate the risk of bronchospasm adasuve must be administered only in an enrolled healthcare facility see warnings and precautions 5 2 adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults efficacy was demonstrated in 2 trials in acute agitation one in schizophrenia and one in bipolar i disorder 1 14 limitations of use adasuve must be administered only in an enrolled healthcare facility 1	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#object object	http://purl.obolibrary.org/obo/DOID_5419 DOID_5419	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate	https://w3id.org/biolink/vocab/treats treats	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject	https://identifiers.org/drugbank:DB00408 drugbank:DB00408	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/association_type association_type	https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/provided_by provided_by	https://w3id.org/um/NeuroDKG NeuroDKG	Leoni Bücken	2021-07-03T10:43:32.281Z
http://purl.org/np/RAPMXaodj3... RAPMXaodj3	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/relation relation	https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication	Leoni Bücken	2021-07-03T10:43:32.281Z